Raghuraj Panchabhai
by on February 3, 2023

Continuous Renal Replacement Therapy Industry Overview

The global continuous renal replacement therapy market size was valued at USD 1.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.5% from 2022 to 2030. Rising incidence of Acute Kidney Injury (AKI), increasing incidence of sepsis, rapid increase in volume of hospitals and urgent care centers, growing hospital admissions rate, and constant product launches by prominent market players are few factors driving the demand for CRRT, thereby propelling market growth. In the pre-COVID-19 era, the burden of COVID-19-associated AKI climbed to almost 4 million cases per year.

As a result, the high number of COVID-19 patients who develop AKI is expected to drive the market for continuous renal replacement therapy over the forecast period. CRRT was utilized to treat roughly 23,105 AKI patients per year prior to COVID-19. The need for CRRT appears to be 5 times higher in COVID-19 patients, i.e., 4.9 percent, then in historical populations (0.9 percent). In community cohort datasets, 5%–15% of people hospitalized with COVID-19 needed dialysis. Moreover, in some North America regions, the number of people utilizing CRRT jumped by 370 percent over normal levels due to which the demand for the product has been increased during pandemic.

Gather more insights about the market drivers, restrains and growth of the Global Continuous Renal Replacement Therapy market

Furthermore, high number of initiatives taken by the manufacturers and government during the pandemic to increase awareness regarding CRRT and CKD is expected to boost the growth of the market for continuous renal replacement therapy. For instance, Fresenius Medical Care North America's Renal Therapies Group (FMCNA) released the first batch of multiBic dialysate solutions to U.S. hospitals in May 2020, according to an FDA emergency use authorization. These medicines are intended to provide CRRT to COVID-19-related individuals with acute renal failure.

Furthermore, the pandemic of COVID-19 has also led in a surge in demand for CRRT in the worldwide. As a result, the market for continuous renal replacement therapy has seen an increase in financial incentives as well as regulatory support from various government agencies. These factors are expected to contribute to the CRRT market's positive growth in the worldwide over the forecast period. Moreover, several studies are being undertaken across the worldwide to assess the demand for CRRT during a pandemic. In February 2021, the journal Kidney360 released a research titled "Meeting the Demand for Renal Replacement Therapy During the COVID-19 Pandemic: A Manufacturer's Perspective." The study looked at the influence of COVID-19 on the CRRT market as well as the link between AKI and COVID-19-affected patients.

AKI was diagnosed in 28 percent to 46 percent of COVID-19 hospitalized patients, according to major U.S. cohorts studied at the onset of the pandemic. Patients requiring admission/transfer to the ICU had significantly higher rates, ranging from 61 percent to 78 percent. Going forward, as lockdown restrictions are being lifted in most of the countries, supply chains of most healthcare companies, including CRRT, are expected to work effectively and smoothly over the forecast period. Thus, the market for continuous renal replacement therapy is expected to grow at a significant rate in the coming years. Moreover, the COVID-19 outbreak has created opportunities for local manufacturers. These firms are adopting various plans and policies to gain a higher market share. Players are partnering with relevant third-party vendors to reinforce their foothold in the market.

The rising prevalence of fluid overload, which is common in AKI patients in critical care units, is increasing demand for CRRT devices. In addition, the FDA has imposed tight regulations requiring manufacturers to ensure the availability of high-quality CRRT devices in intensive care units. Due to COVID-19 pandemic, rate of kidney infections has been increased due to which several CRRT devices such as hemofilter / hemodialyzer, delivery unit, dialysate solution, and bloodlines and tubing have been authorized by FDA for emergency use in COVID-19 patients. For instance, Prismaflex HF20 Set and Prismaflex ST Set by Baxter Healthcare Corporation and multiFiltrate PRO System and multiBic/multiPlus Solutions by Fresenius Medical are specific CRRT and hemodialysis devices authorized by FDA. Thus, COVID-19 is contributing to increase in the demand for CRRT devices during the forecast period.

The increased demand for advanced CRRT devices as a result of improved patient outcomes is a high-impact major driver of the market for continuous renal replacement therapy. The current CRRT technology has made it possible to analyze and respond to technical data in a complete manner. These improvements have resulted in a detailed examination of prescription and delivery patterns, which has had a favorable impact on clinical results from the standpoint of quality assurance. The most recent CRRT machines allow for automated data gathering and uniform language, allowing for cross-institutional comparisons. Several major market manufacturers have introduced sophisticated CRRT machines that use these technologies which is expected to boost the growth of the market.

Furthermore, the development of improved pediatric CRRT products is projected to the market for continuous renal replacement therapy in the near future. Pediatric patients who require CRRT have traditionally been treated with systems that are created and indicated for adults and are not licensed for pediatric usage, which can lead to clinical problems in neonates. As a result, various manufacturers currently offer a range of renal care solutions that enhance access to care, results, and quality of life for patients with severe renal disease or injury anywhere in the globe, regardless of their size or age, which is projected to fuel market expansion.

For instance, December, 2020, the pediatric dialysis emergency machine which is named as Carpediem Cardio-Renal has been commercially launched in the U.S by Medtronic plc. This technology is indicated for use in patients who require hemofiltration or hemodialysis therapy due to acute renal fluid overload or damage. It's designed to give patients who weigh among 2.5 and 10 kilos Continuous Renal Replacement Therapy (CRRT). U.S dominated the market for continuous renal replacement therapy with the highest shares. This can be attributed to rising prevalence of Acute Kidney Injury (AKI) and presence of large number of hospitals in the U.S., coupled with well-developed healthcare infrastructure.

For instance, according to American Hospital Association in 2021, there were 5,141 community hospitals, 625 nonfederal psychiatric hospitals, and 208 federal government hospitals in the U.S. In addition, significant increase in the number of hospital admissions for AKI along with the increasing geriatric populations is boosting the demand for CRRT systems, thereby propelling market growth. Moreover, according to According to the Centers for Disease Control and Prevention’s in 2021, nearly 786,000 people in the U.S are living with ESKD, also known as end-stage renal disease (ESRD), with 71% on dialysis and 29% with a kidney transplant. Thus, with rising prevalence of end-stage renal disease, the number of dialysis clinics and treatment centers is growing. For instance, as of 2020, there were around 7,500 dialysis clinics in the U.S. This factor is expected to positively impact market growth in the U.S.

Browse through Grand View Research's 
Medical Devices Industry Research Reports.

  • Hospital Bedsheet & Pillow Cover Market - The global hospital bedsheet & pillow cover market size was valued at USD 4,586.9 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2021 to 2028.

  • Blood Ketone Meter Market - The global blood ketone meter market size was valued at USD 279.6 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.7% from 2021 to 2028.

Continuous Renal Replacement Therapy Market Segmentation

Grand View Research has segmented the global continuous renal replacement therapy market on the basis of product, modality, and region:

Continuous Renal Replacement Therapy Market, Product Outlook (Revenue USD Million; 2017 - 2030)

  • System
  • Consumables

Continuous Renal Replacement Therapy Market, Modality Outlook (Revenue USD Million; 2017 - 2030)

  • Slow Continuous Ultra-Filtration (SCUF)
  • Continuous Venovenous Hemofiltration (CVVH)
  • Continuous Venovenous Hemodialysis (CVVHD)
  • Continuous Venovenous Hemodiafiltration (CVVHDF)

Continuous Renal Replacement Therapy Market, Age Group Outlook (Revenue USD Million; 2017 - 2030)

  • Adults
  • Pediatrics /Neonates

Continuous Renal Replacement Therapy Market, End Use Outlook (Revenue USD Million; 2017 - 2030)

  • Hospitals
  • Ambulatory Centers
  • Specially Clinics
  • Others

Continuous Renal Replacement Therapy Market, Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)


Market Share Insights

  • March 2021: B. Braun Avitum AG, a manufacturer of pharmaceutical and medical devices services and products, have stated the launch of a global co-marketing contract with B. Braun's latest OMNIset Plus bloodline set (set version 3.0 or higher) and continuous purification of blood (OMNI) platform to support the use of CytoSorb.
  • June 2021: Fresenius Medical Care inaugurated its training center in Korea, to support education for healthcare professionals in critical care, renal care, and treatment strategies.

Key Companies profiled:

Some of the prominent players in the continuous renal replacement therapy market include:

  • Braun Melsungen AG
  • Baxter International, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Asahi Kasei Corporation
  • NIPRO Corporation
  • Toray Medical Co., Ltd
  • NxStage Medical, Inc.
  • Medtronic plc & Others


Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.


Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519



Follow Us: LinkedIn | Twitter

Post in: business
Be the first person to like this.
Page generated in 0.2575 seconds with 17 queries and GZIP enabled on